Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Intangibles (2023 - 2025)

Historic Intangibles for Zevra Therapeutics (ZVRA) over the last 3 years, with Q3 2025 value amounting to $6.7 million.

  • Zevra Therapeutics' Intangibles fell 9045.86% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 9045.86%. This contributed to the annual value of $69.0 million for FY2024, which is 33.8% down from last year.
  • Per Zevra Therapeutics' latest filing, its Intangibles stood at $6.7 million for Q3 2025, which was down 9045.86% from $7.1 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Intangibles high stood at $70.6 million for Q3 2024, and its period low was $6.7 million during Q3 2025.
  • Its 3-year average for Intangibles is $53.0 million, with a median of $67.5 million in 2024.
  • Its Intangibles has fluctuated over the past 5 years, first crashed by 33.8% in 2024, then tumbled by 9045.86% in 2025.
  • Zevra Therapeutics' Intangibles (Quarter) stood at $69.2 million in 2023, then decreased by 0.34% to $69.0 million in 2024, then plummeted by 90.24% to $6.7 million in 2025.
  • Its Intangibles was $6.7 million in Q3 2025, compared to $7.1 million in Q2 2025 and $67.4 million in Q1 2025.